EWTXEdgewise Therapeutics, Inc.

Healthcare
$39.02+174% 1Y

The financials

Edgewise Therapeutics, Inc. by the numbers

The next results filing is expected around Nov 5, 2026, the same week as a year ago.

Edgewise Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$62M−$43Mn/a
Net income−$57M−$36Mn/a
Diluted EPS−$0.53−$0.34n/a

Biotechnology

Ranks #174 of 196 by RyuScore

Compare peers
ERAS+3.8%
Erasca, Inc.
CELC+0.15%
Celcuity Inc.
VKTX+2.8%
Viking Therapeutics, Inc.
TNGX+5.6%
Tango Therapeutics, Inc.
ACAD+1.0%
ACADIA Pharmaceuticals Inc.
MANE+3.0%
Veradermics, Incorporated